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Abstract
Background
Maternal group B streptococcal (GBS) vaccines under development hold promise to prevent
GBS disease in young infants. Sub-Saharan Africa has the highest estimated disease bur-
den, although data on incidence and circulating strains are limited. We described invasive
bacterial disease (IBD) trends among infants <90 days in rural Mozambique during 2001–
2015, with a focus on GBS epidemiology and strain characteristics.
Methods
Community-level birth and mortality data were obtained from Manhic¸a’s demographic sur-
veillance system. IBD cases were captured through ongoing surveillance at Manhic¸a district
hospital. Stored GBS isolates from cases underwent serotyping by multiplex PCR, antimi-
crobial susceptibility testing, and whole genome sequencing.
Results
There were 437 IBD cases, including 57 GBS cases. Significant declines in overall IBD, neo-
natal mortality, and stillbirth rates were observed (P<0.0001), but not for GBS (P = 0.17). In
2015, GBS was the leading cause of young infant IBD (2.7 per 1,000 live births). Among 35
GBS isolates available for testing, 31 (88.6%) were highly related serotype III isolates within
multilocus sequence types (STs) 17 (68.6%) or 109 (20.0%). All seven ST109 isolates
(21.9%) had elevated minimum inhibitory concentration (MIC) to penicillin (0.12 μg/mL)
associated with penicillin-binding protein (PBP) 2x substitution G398A. Epidemiologic and
molecular data suggest this is a well-established clone.
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Conclusion
A notable young infant GBS disease burden persisted despite improvements in overall
maternal and neonatal health. We report an established strain with pbp2x point mutation, a
first-step mutation associated with reduced penicillin susceptibility within a well-known viru-
lent lineage in rural Mozambique. Our findings further underscores the need for non-antibi-
otic GBS prevention strategies.
Introduction
In 2013, an estimated 6.3 million children aged<5 years died globally; more than half of these
deaths were due to infectious causes[1]. Causes with the slowest reduction in under-five mor-
tality rates included congenital abnormalities, preterm birth complications, and neonatal
sepsis[1]. In countries with strong invasive bacterial disease (IBD) surveillance, group B Strep-
tococcus (GBS) is a leading cause of sepsis and bacterial meningitis in the first 90 days of life[2–
4] with a notable portion of cases presenting on the day of birth[5, 6]. GBS has also been asso-
ciated with stillbirths[7, 8] and premature births[9]. A systematic review estimated that the
global incidence of GBS disease in young infants (<90 days) was 0.53 per 1,000 live births and
highest in sub-Saharan Africa (1.21 per 1,000 live births)[10]. Estimated case fatality was also
the highest in this region[10].
In resource-rich countries, intrapartum antibiotic prophylaxis (IAP) has been used to pre-
vent neonatal GBS disease since the 1980s, with success in reducing early-onset (disease onset
during days 0–6) GBS disease [11–13]. However, the impact has been variable in different set-
tings adopting different IAP strategies [14, 15], and IAP has not impacted late-onset (disease
onset during days 7–89) disease[16]. In addition, IAP may not be feasible to implement in
resource-limited settings. In recent years, there has been increasing global interest in maternal
vaccination during pregnancy as a strategy to prevent disease with significant burden among
neonates and infants. The World Health Organization (WHO) Product Development for Vac-
cines Advisory Committee (PDVAC) identified GBS as a priority pathogen[17]. Current GBS
vaccines under development use capsular polysaccharides and surface proteins as the main
vaccine targets, and some have completed phase II clinical trials[18–20].
A better understanding of the GBS disease burden and bacteriologic characteristics in low-
income, high-burden settings will help inform GBS vaccine decision making[17]. However,
current disease burden data from low- and middle-income countries (LMIC) are sparse[10].
Limited access to health care, large proportion of births outside healthcare facilities, and lack
of diagnostic capacity likely contribute to underestimation of the disease burden among young
infants in LMIC[21]. Here, we aimed to describe IBD trends from 2001–2015 among infants
aged<90 days in a rural district in southern Mozambique and characterize clinical and micro-
biological features of early- and late-onset GBS disease.
Materials and methods
Manhic¸a demographic surveillance system
The Manhic¸a Health Research Center (Centro de Investigac¸ão em Sau´de de Manhic¸a, CISM)
is located in a rural area 80 km north of Maputo, Mozambique. Since 1996, CISM has run a
continuous demographic surveillance system (DSS), which captures births, deaths, causes of
deaths, maternity, in and out migration, and pregnancies from a defined catchment area[22,
23]. Causes of deaths in the area are obtained through verbal autopsy using methods based on
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the WHO model. There is perennial malaria transmission in the area, mostly due to Plasmo-
dium falciparum[24] and high HIV prevalence (23.6%) among pregnant women[25]. Vaccines
against Haemophilus influenzae type b (Hib) and the 10-valent pneumococcal conjugate vac-
cine (PCV10, three doses at 2, 3, and 4 months) were introduced into the national immuniza-
tion program in 2009 and 2013, respectively[26]. The DSS catchment area expanded in phases,
starting with the town of Manhic¸a in 1996 (100 km2, approximately 34,000 residents), the
addition of surrounding neighborhoods in 2002 and 2005, and expansion to the entire Man-
hic¸a district in 2014 (2,380km2, population size of 175,000). The DSS catchment contains 12
health centers and two referral district hospitals; most patients requiring admission are ref-
erred to the Manhic¸a district hospital (MDH). Young infants with illness requiring intensive
care, including those<28 weeks of gestation or very low birth weight (<1,500g), are trans-
ferred to the national referral hospital (Maputo Central Hospital) in Maputo.
Invasive bacterial disease surveillance
Since January 1997, CISM and MDH have jointly operated pediatric IBD surveillance, in-
cluding capture of young infant infections, through round-the-clock surveillance of pediatric
outpatient department visits and hospital admissions. Trained healthcare workers use stan-
dardized forms to record physical examination findings and clinical signs reported by the care-
giver upon admission[23, 27]. A single venous blood specimen for bacterial culture is collected
from all young infants before hospital admission. Cerebrospinal fluid (CSF) collection is rec-
ommended for any neonate (age28 days) or older infants with a reported history of convul-
sions, agitation, unconsciousness, or depressed or tense fontanelle on examination. Recovered
isolates are stored in a biobank. Additional laboratory test results (e.g., blood glucose, blood
smears), treatment details, discharge diagnoses, and hospital outcome are recorded. Forms
were double entered in FoxPro (version 2.6, Microsoft Corporation, Redmond, WA, USA) at
CISM and discrepancies in data entry were resolved by referring to the original forms. IBD
surveillance data are linked to the DSS records.
Laboratory procedures
Approximately 1 ml of whole blood was immediately inoculated into one pediatric blood cul-
ture bottle (Pedibact1; Becton-Dickinson, Franklin Lakes, NJ, USA), which was incubated in
an automatic BACTEC1 9050 system (Becton-Dickinson) for 5 days. Blood culture bottles
with growth detected were subcultured onto blood agar and incubated overnight at 37˚C in
5% CO2 for 18–24 hours. CSF samples first underwent cytological examination and Gram
stain, and were subsequently cultured onto blood agar, chocolate agar and thioglycolate broth
media for 24 hours and, if negative, up to 5 days at 37˚C in an atmosphere of 5% CO2. Thiogly-
colate broths with turbidity were stained and subcultured on blood agar media and incubated
for 48 hours. Bacterial isolates were identified according to standard microbiologic procedures
as described previously[27]. Typical colonies of GBS were identified by beta-hemolysis or non-
hemolysis (nonhemolytic variant), Gram stain compatible with Streptococcus spp., negative
catalase reaction, bacitracin resistance, and detection of the Lancefield group B antigens by
a rapid latex agglutination test (Bio RAD PASTOREXTM STREP). GBS isolates were sent to
the Streptococcus Laboratory at the U.S. Centers for Disease Control and Prevention (CDC),
Atlanta, for serotyping by multiplex PCR, antimicrobial susceptibility testing by broth micro-
dilution using Clinical and Laboratory Standards Institute minimum inhibitory concentration
(MIC) breakpoints[28], and whole genome sequencing (WGS). If both blood and CSF isolates
were available from the same child, the CSF isolate was selected for WGS. WGS procedures for
serotype deduction, deduction of antimicrobial susceptibility profiles, and MLST are described
Invasive bacterial disease and GBS isolate characterization among young infants in southern Mozambique
PLOS ONE | https://doi.org/10.1371/journal.pone.0191193 January 19, 2018 3 / 16
in detail elsewhere[29, 30]. For determination of presence or absence of certain surface pro-
teins implicated in adhesion, carriage, and disease, we employed sequence queries for the
CC17-associated virulence factor (hypervirulent GBS adhesin, HvgA), three different pili (PI1,
PI2a and PI2b-1), four different Alpha C family proteins (Alp1, Alp2-3, Alpha, Rib), and the
two serine rich repeat proteins (SRR1 and SRR2) (S1 Table). Our designated Alp2-3, a close
homolog of the group A Streptococcus R28 antigen[31], is representative of one of four mutu-
ally exclusive, distinct Alpha C family genetic determinants detected through our pipeline.
PI2a1 and PI2a2 are subclasses of the backbone protein subunit PI2a [32]. The bioinformatics
pipeline is described athttps://github.com/BenJamesMetcalf/GBS_Scripts_Reference. To per-
form single nucleotide polymorphism analysis, paired-end fastq files were trimmed with Cuta-
dapt v 1.8.1 and draft genome assemblies were constructed using VelvetOptimiser v 2.2.5 with
an optimal kmer value calculated by VelvetK. Core genome SNP identification and alignment
were carried out using kSNP3.0[33].
Definitions
Microbiologically-confirmed IBD was defined as a positive blood or CSF culture from a young
infant from the DSS catchment area admitted to MDH. Coagulase-negative staphylococci, group
viridans streptococci, and gram-positive bacilli (e.g., Corynebacterium spp., Bacillus spp.) were
considered contaminants. Early-onset disease (EOD) was defined as IBD in children aged<7
days, and late-onset disease (LOD) as IBD in children aged 7–89 days. Possible serious bacterial
infection (PSBI) was defined by any one of the following signs: poor feeding, history of convul-
sions according to the caregiver’s report, healthcare worker observation of fast breathing (defined
as respiratory rate of60 per minute in a child 0–59 days and50 per minute in a child 60–89
days), chest indrawing, fever (38.0˚C), low body temperature (35.5˚C<), or unconsciousness.
Statistical analysis
We calculated annual IBD incidence rate, neonatal mortality rate, and admission rate using
the number of live births per year within the DSS catchment area as the denominator. Annual
stillbirth rates were calculated using the number of births (live births and stillbirths) as the
denominator. Due to time lags in finalization of DSS data, neonatal mortality rate was evalu-
ated from 2001–2013 and verbal autopsy data from 2001–2011. Proportions were compared
using chi-square or Fisher’s exact tests. Trends of rates were assessed using Poisson regression
and trends of proportion were assessed using the Cochran-Armitage trend test. All analyses
were conducted in SAS 9.4 (SAS Institute, Inc., Cary, North Carolina).
Ethics
This study retrospectively assessed data collected in the context of routine surveillance. As part
of the DSS and IBD surveillance procedure, written consent is obtained from all heads of
households and adult participants to use their and their children’s data (if age<18 years) for
research conducted by CISM. The IBD surveillance system was reviewed and approved by the
Mozambican National Bioethics Committee and institutional review boards of Hospital Clinic
of Barcelona, Spain, the U.S. CDC and the University of Maryland, School of Medicine.
Results
During 2001–2015, a total of 47,651 live births and 993 stillbirths were reported within the
DSS catchment (Fig 1, S2 Table). The number of annual live births tripled from 2001 (1,370)
to 2015 (4,120), reflecting the DSS expansion. In 2014–15 (years where birth location was
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captured) most (93.7%) births occurred at health facilities. Both stillbirth and neonatal mortal-
ity rates declined during the study period (stillbirths: 38.6 per 1,000 births in 2001 to 5.6 per
1,000 births in 2015, P<0.0001; neonatal mortality: 35.8 per 1,000 live births in 2001 to 16.7
per 1,000 live births in 2013, P<0.0001) (Fig 2). Among infants <90 days, 2,257 deaths were
reported. Based on verbal autopsy records (2001–2011), 53.6% of young infant deaths occurred
at a health facility (P = 0.66 for trend); leading causes of death were respiratory and cardiovas-
cular diseases specific to the perinatal period (19.8%), disorders related to length of gestation
and fetal growth (14.5%), and infection specific to the perinatal period (12.9%) (S3 Table).
A total of 4,393 admissions of children aged<90 days was recorded at MDH (range: 206–
388 per year). The admission rate decreased from 151 per 1,000 live births in 2001 to 59 per
1,000 live births in 2015 (P<0.0001). Of all admissions, 91% (3,997/4,393) had blood or CSF
culture collected (78.5% for day 0–2 infants vs. 90.7% for day3 infants; P<0.0001) and 9.9%
(437/4,393) had IBD (EOD: 23.1%; LOD: 76.9%) (Fig 1). Median age of onset of infants with
Fig 1. Summary of young infants aged<90 days admitted for invasive bacterial disease, Manhic¸a demographic
and health surveillance system, Mozambique, 2001–2015.
https://doi.org/10.1371/journal.pone.0191193.g001
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IBD was 15 days (interquartile range [IQR] 7–29) (S1 Fig); 13.1% had been seen at another
healthcare facility before admission and 76.0% had signs consistent with PSBI (Table 1). Fast
breathing (51.4%) and fever (37.0%) were the most common signs (S5 Table). Of the 354 with
information on antibiotic administration, most (98.6%) infants with IBD received antibiotic
Fig 2. Trends of invasive bacterial disease and neonatal mortality rates (per 1,000 live births) during 2001–2015 and stillbirth rate
(per 1,000 births) during 2001–2013, Manhic¸a, Mozambique.
https://doi.org/10.1371/journal.pone.0191193.g002
Table 1. Descriptive characteristics of young infants days 0–89 of age with IBD, Manhic¸a demographic and health surveillance system, Mozambique, 2001–2013.
Characteristics All IBD
N = 437
No (%)
All GBS
N = 57
No (%)
GBS
EOD
N = 19
no (%)
LOD
N = 38
no (%)
Sex
Male 239 (54.7%) 30 (52.6%) 10 (52.6%) 20 (52.6%)
Median age in days (IQR) 15 (7–29) 10 (4–15) 0 (0–4) 13 (10–17)
Median weight upon admission, kg (IQR)1 3.3 (2.8–3.8) 3.0 (2.7–3.4) 2.9 (2.6–3.1) 3.1 (2.8–3.5)
Child is breastfed2 320 (90.4%) 44 (91.7%) 16 (94.1%) 28 (90.3%)
Caregiver previously sought care for child’s condition3
Yes 57 (13.1%) 4 (7.0%) 2 (10.5%) 2 (5.3%)
No 377 (86.7%) 53 (93.0%) 17 (89.5%) 36 (94.7%)
PSBI present upon admission4
Yes 322 (76.0%) 47 (82.5%) 17 (89.5%) 30 (79.0%)
No 105 (24.0%) 10 (17.5%) 2 (10.5%) 8 (21.1%)
Clinical signs reported by the caregiver
History of convulsions5 18 (4.2%) 3 (5.3%) 2 (10.5%) 1 (2.6%)
(Continued)
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treatment, primarily aminoglycosides (gentamicin) (79.9%) and ampicillin or amoxicillin
(73.6%). Of those with IBD, 51 (11.8%) died during the hospital stay, compared to 216 of 3956
(5.5%) admitted infants without IBD (P<0.0001) (Fig 1).
Overall, Staphylococcus aureus was the most frequently isolated pathogen (n = 134, 2.8 per
1,000 live births), followed by GBS (n = 57, 1.2 per 1,000 live births) and Streptococcus
Table 1. (Continued)
Characteristics All IBD
N = 437
No (%)
All GBS
N = 57
No (%)
GBS
EOD
N = 19
no (%)
LOD
N = 38
no (%)
Cough6 182 (41.7%) 17 (29.8%) 2 (10.5%) 15 (39.5%)
Difficult breathing7 150 (34.6%) 22 (39.3%) 10 (52.6%) 12 (32.4%)
Unable to drink or breastfeed8 82 (18.9%) 17 (29.8%) 10 (52.6%) 7 (18.4%)
Diarrhea 42 (9.6%) 1 (1.8%) 1 (5.3%) 0
Vomiting 42 (9.6%) 3 (5.3%) 1 (5.3%) 2 (5.3)
Type of specimen
Blood only 266 (60.9%) 33 (57.9%) 12 (63.2%) 21 (55.3%)
Blood and CSF 171 (39.3%) 24 (42.1%) 7 (36.8%) 17 (44.7%)
Meets criteria for CSF culture 348 (79.6%) 56 (98.3%) 19 (100%) 37 (97.4%)
CSF collected among those who have indications for collection9 171 (49.1%) 24 (42.9%) 7 (36.8%) 17 (45.9%)
CSF culture positive 53/171 (31.0%) 15/24 (62.5%) 5/7 (71.4%) 10/17 (58.8%)
Antibiotic treatment given10 349 (98.6%) 46 (95.8%) 16 (94.1%) 30 (96.8%)
Penicillin 57/349 (16.3%) 4/46 (8.7%) 1/16 (6.3%) 3/30 (10.0%)
Cotrimoxazole 25/349 (7.2%) 0 0 0
Chloramphenicol 15/349 (4.3%) 0 0 0
Gentamicin 279/349 (79.9%) 33/46 (71.7%) 10/16 (62.5%) 23/30 (76.7%)
Ampicillin/Amoxicillin 257/349 (73.6%) 36/46 (78.3%) 11/16 (68.8%) 25/30 (83.3%)
Erythromycin 8/348 (2.3%) 0 0 0
Cephalosporins 90/348 (25.9%) 15/46 (32.6%) 8/16 (50.0%) 7/30 (23.3%)
Outcome of hospital stay
Discharged 330 (75.5%) 48 (84.2%) 12 (63.2%) 36 (94.7%)
Died 51 (11.7%) 7 (12.3%) 6 (31.6%) 1 (2.6%)
Others11 56 12.8%) 2 (3.5%) 1 (5.3%) 1 (2.6%)
CSF = cerebrospinal fluid. EOD = early-onset disease. GBS = group B streptococcus. IBD = invasive bacterial disease. IQR = interquartile range. LOD = late-onset
disease. PSBI = possible serious bacterial infection.
1.17 missing data
2. 83 were missing data, and the percentage was calculated excluding those with missing information (9 missing for GBS: EOD 2, LOD 7).
3. 3 were missing data (none among GBS cases), and the percentage was calculated excluding those with missing information.
4.Defined as presence of either: unable to drink or breastfeed, history of convulsions, fast breathing, chest indrawing, fever (38.0˚C), low body temperature (35.5˚C<),
unconscious
5. 4 were missing data (none among GBS cases), and the percentage was calculated excluding those with missing information.
6. 1 was missing data (none among GBS cases), and the percentage was calculated excluding those with missing information.
7. 3 were missing data, including 1 LOD case. The percentage was calculated excluding those with missing information.
8. 2 were missing data (none among GBS cases), and the percentage was calculated excluding those with missing information.
9.Any neonate28 days or infants 28 days with any of the following: depressed or tense fontanelle; convulsions reported by the caregiver; agitated or unconscious
10. 83 were missing data on antibiotic treatment, including 9 among GBS cases (2 EOD, 1 LOD). The percentage was calculated excluding those with missing
information.
11.Transferred, left against medical advice, or missing data (4 cases, none among GBS cases).
https://doi.org/10.1371/journal.pone.0191193.t001
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pneumoniae (n = 54, 1.1 per 1,000 live births) (Table 2). The overall IBD incidence rate
declined significantly during the study period (19.2 per 1,000 live births in 2001 to 6.6 per
1,000 live births in 2015; P<0.0001) (Fig 2). Incidence rates declined significantly for S. aureus,
S. pneumoniae, group D streptococcus, Escherichia coli, and nontyphoidal Salmonella (Table 2,
S2A and S2B Figs), but not for GBS (Table 2, Fig 3). GBS incidence rate peaked in 2005 at 3.7
per 1,000 live births, had a low, stable incidence from 2008–2011 (0.3 per 1,000 live births) and
increased again to become the leading IBD pathogen in 2015 (2.7 per 1,000 live births) (S2A
Fig).
Among the 57 young infants with invasive GBS disease, 19 had EOD and 38 had LOD
(Table 1). GBS LOD incidence rates were equal to or higher than EOD incidence rates except
for 2009, 2011 and 2014. Median age of onset was 10 days (EOD: day 0, LOD: day 13) and
24.6% (14/57) of GBS cases occurred during days 0–2, particularly on day 0 (10/57, 17.5%) (S1
Fig). CSF was collected in 42.1% of infants with GBS IBD; 62.5% of those were positive (71.4%
for EOD, 58.8% for LOD). Mortality was higher among infants with EOD; approximately one-
third of GBS EOD admissions resulted in death (Table 1).
A total of 35 GBS isolates (60% blood, 40% CSF; 88.6% from 2010 or later; 62.9% LOD)
were available for characterization (Table 3, S4 Table). Almost all isolates (33 of 35, 94.3%)
were serotype III. Serotype III isolates were all within clonal complex (CC) 17 (sequence type
Table 2. Bacterial isolations and incidence of invasive infections among young infants, Manhica demographic and health surveillance system, Mozambique, 2001–
2015.
Species Rate per 1000 live births1 (no.) p value for trend over time2
Overall Day 0–2 of life Day 3–6 Day 7–27 Day 28–89
Gram positive 63 (307) 3 11 (52) 03 (13) 36 (175) 14 (67) <00014
Staphylococcus aureus 28 (134) 04 (20) 01 (5) 19 (90) 04 (19) <00014
Group B streptococcus 12 (57) 03 (14) 01 (5) 07 (35) 006 (3) 017
Streptococcus pneumoniae 11 (54) 006 (3) 002 (1) 03 (14) 07 (36) 00014
Group D streptococcus 07 (35) 03 (14) 004 (2) 03 (14) 01 (5) <00014
Group A streptococcus 04 (18) 0 0 03 (16) 004 (2) 026
Others 02 (10) 002 (1) 0 01 (6) 006 (3) 010
Gram negative 28 (137) 5 06 (27) 03 (12) 10 (47) 10 (50) <00014
Escherichia coli 07 (32) 01 (7) 010 (5) 02 (11) 02 (9) 0044
Nontyphoidal Salmonella6 05 (23) 002 (1) 004 (2) 03 (12) 02 (8) 00024
Haemophilus influenzae7 03 (14) 0 0 002 (1) 03 (13) 019
Klebsiella spp. 8 02 (12) 008 (4) 002 (1) 008 (4) 006 (3) 013
Pseudomonas spp.9 02 (9) 002 (1) 0 008 (4) 008 (4) 055
Neisseria meningitidis 012 (6) 0 0 004 (2) 008 (4) 030
Enterobacter spp. 10 010 (5) 008 (4) 0 002 (1) 0 083
Others 07 (36) 02 (11) 008 (4) 03 (12) 02 (9) 00054
1.Total live births within the actual DSS during the study period, 2001–2015, N = 47,651
2.Poisson regression assessing the incidence rate trend over time
3. One patient had both S. aureus and GAS isolated
4.p<005
5. One patient had both E. coli and Klebsiella spp. isolated
6. Includes Salmonella Typhimurium, Salmonella Enteritidis, Salmonella Heidelberg, Salmonella Isangi, and Salmonella spp.
7.Includes non-type b H. influenzae
8 Includes K. pneumoniae, K. oxytoca, Klebsiella spp.
9.Includes P. aeruginosa, P.paucimobilis, Pseudomonas spp.
10.Includes E. cloacae, E. aglomerans, E. sakazakii, E. aerogenes
https://doi.org/10.1371/journal.pone.0191193.t002
Invasive bacterial disease and GBS isolate characterization among young infants in southern Mozambique
PLOS ONE | https://doi.org/10.1371/journal.pone.0191193 January 19, 2018 8 / 16
[ST] 17 and its single locus variants ST109, 866, and 1089), and were uniformly positive for the
surface protein genes hvgA, srr2, rib, and for pilus subunit genes (PI1 and PI2b). The two unre-
lated non-serotype III isolates (serotype V/ST1 and serotype Ia/ST23) had different surface
protein gene profiles, including the absence of the CC17-associated virulence factor (HvgA).
All 35 isolates were resistant to tetracycline, corresponding to the presence of tetM gene
(Table 3). Erythromycin resistance was identified in seven isolates; six were mef-positive (all
serotype III) and one was ermTR-positive (serotype V) with inducible clindamycin resistance.
Notably, all seven (21.9%) isolates with serotype III ST109 had a penicillin MIC of0.12 μg/
mL (five [15.6%] at 0.12 μg/mL, two [6.3%] at 0.25 μg/mL). All ST109 isolates had the unique
PBP2x type PBP2x-39 (see ref [30] for the PBP2x typing scheme). Type PBP2x-39 contains
three substitutions relative to the susceptible reference PBP2x transpeptidase domain sequence
(I377V, G398A, G627V). It is likely that the G398A substitution confers the reduced suscepti-
bility phenotype, since the other two substitutions are commonly found among basally beta-
lactam susceptible GBS isolates[30]. These seven isolates were collected in different years
(2005–2015) and each differed by 39–74 SNPs (S3 Fig).
Discussion
GBS was a leading cause of IBD in Manhic¸a. About two-thirds of all GBS cases were LOD, the
majority of GBS isolates were serotype III, and, though unexpected, there was molecular evi-
dence of isolates with elevated MIC to penicillin. Although overall IBD incidence rates, neona-
tal mortality rates, and stillbirth rates decreased significantly during the study period, GBS
Fig 3. Trends of invasive GBS disease incidence rates in young infants (<90 days), Manhic¸a, 2001–2015.
https://doi.org/10.1371/journal.pone.0191193.g003
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rates were nearing a peak at the end of the study period, highlighting that the disease burden
may not decrease without targeted interventions.
Pathogen-specific interventions that took place during this period included the introduc-
tion of Hib vaccine (2009) and PCV10 (2013). However, Hib IBD cases in this age group were
already rare pre-vaccine and PCV10 introduction would not account for the observed IBD
trend prior to 2013. Decrease in admission rates could have led to decreased IBD case ascer-
tainment, but would not explain reductions in neonatal mortality and stillbirth rates in the
community. Rather, the observed reductions in IBD, neonatal mortality, and stillbirth rates are
likely due to other health interventions that took place during the study period, as well as gen-
eral economic improvements in Mozambique: tetanus toxoid immunization contributed to
elimination of maternal and neonatal tetanus nationwide in 2010[34], intermittent preventive
treatment for malaria in pregnancy (IPTp) was introduced nationwide in 2006[35], and mater-
nal access to HIV antiretroviral therapy increased from 34% in 2009 to 95% in 2015[36, 37].
Improvements in clean birth practices and access to appropriate interventions for sick neo-
nates (e.g., anticonvulsants, antibiotics) may also have contributed[37].
Our results underestimate the actual GBS disease burden, particularly that of EOD. Between
80 to 90% of GBS EOD cases typically occur during the first 24 hours of life[38] and about
two-thirds of young infant disease are EOD[10, 39]; however, day 0 cases were only 17.5% of
all GBS cases in our study. In MDH, day 0–2 infants were less likely to have cultures collected
compared to older infants. Thus, even with our established demographic and IBD surveillance
systems, ascertainment of IBD in the first days of life remained challenging. Additionally, we
may have missed GBS cases among infants who were transferred to the national referral hospi-
tal; however, the number of GBS cases among these infants is likely to be very small.
The predominance of serotype III GBS isolates may be due to the overrepresentation
of LOD, as LOD has been associated with higher proportion of serotype III[10, 39]. Interest-
ingly, the seven ST109 isolates had phenotypic evidence of elevated MIC to penicillin (MIC
0.12 μg/ml), supported by the presence of a new PBP2x type that contains a G398A substitu-
tion. It is known that amino acid substitutions closely adjacent to the conserved 402SSN404 or
552KSG554 motifs are often associated with reduced affinity for beta-lactam antibiotics[40, 41].
Epidemiologic data and phylogenic analyses of the seven ST109 isolates suggest this clone with
elevated MIC to penicillin is well-established in the community and was not introduced by a
point source. Historically, GBS has been pan-susceptible to beta-lactam antibiotics; however,
emergence of GBS isolates with reduced beta-lactam susceptibility has raised concerns about
the sustainability of penicillin or ampicillin as first-line antibiotics for IAP and treatment of
infection[16]. Existing reports on GBS isolates with reduced susceptibility to penicillin have
primarily been from Japan and North America among isolates from older age groups[41–43].
A recent U.S. study reported that 0.7% of the invasive GBS disease isolates had reduced suscep-
tibility to penicillin (defined as MIC0.25 μg/ml)[43], which is much lower than the finding
in our study (6.3%), although our study was limited by the number of samples. A survey of
1975 invasive GBS disease isolates recovered in the United States during 2015 revealed only
one isolate with reduced penicillin susceptibility[30], although 14 of the 1975 isolates (0.7%)
contained first step pbp2x mutations conferring reduced susceptibility to beta-lactam antibiot-
ics other than penicillin[30]. Molecular characterization of GBS isolates in sub-Saharan Africa
has been rare[7] and, to our knowledge, this is the first molecular evidence of GBS isolates
with reduced penicillin susceptibility in sub-Saharan Africa.
Our study is subject to limitations. First, there is a time-lag from when DSS events such as
stillbirths and neonatal deaths occur to when they are captured and frequency of household
visits by the DSS team decreased from twice a year to once a year in 2012. Thus, DSS event
ascertainment may be lower in the more recent years. Second, the definition of IBD was based
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on a single positive culture result, so we may have included some cases based on isolates that
were contaminants. Third, we did not have access to maternal data, in particular HIV status.
Since exposure to HIV may increase the risk of LOD in particular[6, 44], maternal HIV status
would provide a useful context for interpreting the high proportion of LOD we observed.
Fourth, only a portion of GBS isolates were available for laboratory analyses. A larger sample
size would allow for a more robust description of invasive disease strains. Lastly, our results
are an underestimate of the true IBD burden, as described earlier.
Despite these limitations, we documented a notable young infant GBS disease burden
despite reductions in overall IBD rate and broader improvements in maternal and neonatal
health. In addition, this is the first report describing molecular characteristics of GBS isolates
with reduced penicillin susceptibility in sub-Saharan Africa. Our findings that these isolates
are established in this rural community and may be more prevalent in this region than previ-
ously considered, further underscore the need for non-antibiotic GBS prevention strategies
such as maternal immunization.
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